title: Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
abstract: BACKGROUND
  Most adults with Pompe disease are compound heterozygotes in which one acid α-glucosidase (GAA) allele harbors the c.-32-13T>G mutation, causing partial loss of GAA, and the other allele harbors a fully deleterious mutation. The fibroblast GAA activity in these patients is usually between 5% and 25% of the average in healthy individuals. In some adult patients, however, the fibroblast GAA activity is much lower and is in the range that is normally observed in classic-infantile Pompe disease. We investigated the genotype-phenotype correlation in three such adult patients and measured the GAA activity as well as the glycogen content in muscle and fibroblasts in order to better understand the clinical course.
  
  
  METHODS
  DNA was sequenced and GAA activity and glycogen content were measured in leukocytes, fibroblasts and muscle. Muscle biopsies were microscopically analyzed and the biosynthesis of GAA in fibroblasts was analyzed by immunoblotting. GAA activity and glycogen content in fibroblasts and muscle tissue in healthy controls, adult patients with Pompe disease and classic-infantile patients were compared with those of the three index patients.
  
  
  RESULTS
  One patient had genotype c.525delT/c.671G>A (r.0/p.Arg224Gln). Two affected brothers had genotype c.569G>A/c.1447G>A (p.Arg190His/p.Gly483Arg). In all three cases the GAA activity and the glycogen content in fibroblasts were within the same range as in classic-infantile Pompe disease, but the activity and glycogen content in muscle were both within the adult range. In fibroblasts, the first step of GAA synthesis appeared unaffected but lysosomal forms of GAA were not detectable with immunoblotting.
  
  
  CONCLUSIONS
  Some adult patients with mutations other than c.-32-13T>G can have very low GAA activity in fibroblasts but express higher activity in muscle and store less glycogen in muscle than patients with classic-infantile Pompe disease. This might explain why these patients have a slowly progressive course of Pompe disease.
authors.affiliation: Department of Neurology, Erasmus MC, Rotterdam, The Netherlands.
authors.forename: Stephan C A
authors.initials: SC
authors.lastname: Wens
authors.forename: Marian A
authors.initials: MA
authors.lastname: Kroos
authors.forename: Juna M
authors.initials: JM
authors.lastname: de Vries
authors.forename: Marianne
authors.initials: M
authors.lastname: Hoogeveen-Westerveld
authors.forename: Mark G J M
authors.initials: MG
authors.lastname: Wijgerde
authors.forename: Pieter A
authors.initials: PA
authors.lastname: van Doorn
authors.forename: Ans T
authors.initials: AT
authors.lastname: van der Ploeg
authors.forename: Arnold J J
authors.initials: AJ
authors.lastname: Reuser
mesh_terms: D000328:Adult; D000483:Alleles; D005347:Fibroblasts / Q000201:enzymology* / Q000473:pathology; D056726:Genetic Association Studies; D005838:Genotype; D006003:Glycogen / Q000378:metabolism*; D006009:Glycogen Storage Disease Type II / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology; D006579:Heterozygote; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000201:enzymology* / Q000473:pathology; D009154:Mutation; D010641:Phenotype; D000520:alpha-Glucosidases / Q000235:genetics / Q000378:metabolism*
chemical_list: D006003:Glycogen; D000520:alpha-Glucosidases